TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16286672
Drug: HMB/KIC (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB/KIC (3 g HMB and 0.3 g alpha-ketoisocaproic acid, daily)
Study: 12000379
Drug: CDP850 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP850 (20 mg kg-1 intravenously as a single dose)
Study: 9865985
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime 200 mg combined with probenecid 500 mg three times daily for 100 days
Study: 9865985
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 2 g daily for 14 days followed by oral amoxicillin 500 mg combined with probenecid 500 mg three times daily for 100 days
Study: 809253
Drug: Oral TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TRH
Study: 12884360
Drug: Altered lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altered lipid diets (fish oil supplement or seafood diet)
Study: 10833208
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg intramuscularly once weekly for 40 weeks
Study: 10833208
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg intramuscularly once weekly
Study: 8799522
Drug: Sinemet CR
Normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sinemet CR (levodopa 200 mg/carbidopa 50 mg)
Study: 8799522
Drug: Sinemet-Plus (levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet-Plus (levodopa 100 mg/carbidopa 25 mg)
Study: 8799522
Drug: Benzhexol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzhexol (2 mg tablets)
Study: 1483496
Drug: Oral famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral famotidine (40 mg)
Study: 31037285
Drug: Aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2.0 mg intravitreous injection every 4 weeks)
Study: 27977439
Drug: Bilateral sternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sternal infusion of 0.2% ropivacaine (3 ml/h through each catheter)
Study: 27977439
Drug: Bilateral sternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sternal infusion of 0.2% ropivacaine
Study: 18575355
Drug: Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatment (computer cognitive rehabilitation) consisting of 12 individual sessions of computer exercises
Study: 18575355
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (aspecific treatment) consisting of semi-structured interviews with patients
Study: 3183034
Drug: Lymphoblastoid interferon
Normalized name: interferon alfa-n1 lymphoblastoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid interferon administered daily for 6 months
Study: 31615466
Drug: Sequential HAIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential HAIC with cisplatin followed by sorafenib
Study: 27671836
Drug: 2-hourly feeding
Normalized name: BAGS,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hourly feeding
Study: 27671836
Drug: 3-hourly feeding
Normalized name: SYRINGE,FEEDING ENFIT 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hourly feeding
Study: 11097146
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 100 mg twice daily for one week
Study: 9067912
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of treatment after 4 years
Study: 9067912
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (N = 20) with largest initial treatment-induced fall in GFR
Study: 9067912
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of treatment in Group A
Study: 9067912
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of treatment in Group B
Study: 9067912
Drug: Post-treatment GFR
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment GFR in Group A
Study: 9067912
Drug: Post-treatment GFR
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment GFR in Group B
Study: 3716914
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking and caffeine administration during task performance
Study: 24720741
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1600 µl
Study: 24720741
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1200 µl
Study: 24720741
Drug: Thigh injections
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh injections
Study: 11836328
Drug: High-dose testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose testosterone (200 mg) in older men
Study: 11836328
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone (100 mg) in young men
Study: 8907566
Drug: Alpha-interferon treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-interferon treatment
Study: 1919966
Drug: Prism adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism adaptation preoperative treatment
Study: 7128838
Drug: Danazol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (800 mg daily for the first 2 months, 600 mg daily for the next 2 months, and 400 mg daily for the final 2 months)
Study: 10213347
Drug: Glimepiride (1.162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1.162 mg)
Study: 10213347
Drug: Glibenclamide (2.54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.54 mg)
Study: 14317
Drug: Dipotassic chlorazepate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipotassic chlorazepate, paracetamol and codeine (individual components)
Study: 17350342
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with AEDs
Study: 12358962
Drug: Multimodal anti-emetic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal anti-emetic prophylaxis including total intravenous anaesthesia with propofol, high fractional inspired oxygen (80%), omission of nitrous oxide, dexamethasone 8 mg, haloperidol 10 microg.kg(‐1), and tropisetron 2 mg.
Study: 535145
Drug: Radical radiotherapy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiotherapy and/or chemotherapy
Study: 535145
Drug: Serial determinations
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial determinations post-treatment
Study: 31531552
Drug: self‐etch/bulk‐fill in
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐etch/bulk‐fill in capsules
Study: 31531552
Drug: selective enamel‐etching/bulk‐fill
Approvals — FDA: no, EMA: no, PMDA: no
Description: selective enamel‐etching/bulk‐fill in capsules
Study: 31531552
Drug: bulk‐fill composite
Approvals — FDA: no, EMA: no, PMDA: no
Description: bulk‐fill composite (capsules or syringes)
Study: 25048310
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (4 mg/kg/day)
Study: 25048310
Drug: Usual-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual-dose prednisolone (2 mg/kg/day)
Study: 22351891
Drug: Amoxicillin (post-CPG)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (post-CPG)
Study: 22351891
Drug: Cefdinir and
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir and amoxicillin/clavulanate (post-CPG)
Study: 19483319
Drug: Kampo preparation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kampo preparation, byakkokaninjinto (TJ‐34)
Study: 12377966
Drug: G17DT 250
Normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G17DT 250 micro g
Study: 12377966
Drug: G17DT 100
Normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G17DT 100 micro g
Study: 12377966
Drug: G17DT (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: G17DT (both doses)
Study: 9881078
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salvage therapy and high dose chemo(radio)‐therapy with stem cell support
Study: 338256
Drug: Bumetanide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (mean 1.3 mg/day, doses varied from 1 mg on alternate days to 3 mg daily)
Study: 338256
Drug: Frusemide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (mean 72 mg/day, doses varied from 40 mg on alternate days to 160 mg daily)
Study: 30897068
Drug: Oral spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral spironolactone (SPRL)
Study: 29652086
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment after open surgery
Study: 29652086
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment after EVLA
Study: 29652086
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment after UGFS
Study: 29652086
Drug: UGFS without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UGFS without further GSV treatment
Study: 28471726
Drug: blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: blended cognitive behavior therapy (bCBT)
Study: 25297344
Drug: Caffeine (400 mg)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (400 mg)
Study: 21981455
Drug: Intravenous phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenylephrine (PE) infusion
Study: 10966544
Drug: Pilsicainide 150
Normalized name: Pilsicaïnide
DrugBank: Pilsicainide (DB12712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilsicainide 150 mg/day for 4 weeks before electrical cardioversion
Study: 10966544
Drug: Pilsicainide 150
Normalized name: Pilsicaïnide
DrugBank: Pilsicainide (DB12712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilsicainide 150 mg/day after successful cardioversion
Study: 8888359
Drug: ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.15 mg/kg, i.v.)
Study: 1310889
Drug: Intra-arterial cisplatin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered concomitant with radiation therapy
Study: 1310889
Drug: Intra-arterial cisplatin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered sequentially with radiation therapy
Study: 1310889
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment arm
Study: 1310889
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy arm
Study: 6380363
Drug: Cefuroxime plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime plus metronidazole (1.5 g cefuroxime plus 500 mg metronidazole)
Study: 6380363
Drug: Metronidazole alone
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole alone (500 mg metronidazole)
Study: 31636065
Drug: GLS4 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS4 120 mg with ritonavir 100 mg
Study: 31636065
Drug: GLS4 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS4 alone (multiple dosing)
Study: 31636065
Drug: GLS4 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS4 240 mg with ritonavir 100 mg (placebo control)
Study: 31636065
Drug: GLS4 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS4 240 mg (single and multiple doses)
Study: 30149375
Drug: Voice exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice exercises with water resistance therapy at 4 and 8 cm of water depth
Study: 30149375
Drug: Voice exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice exercises with water resistance therapy at 8 cm
Study: 26267328
Drug: 200 μg selenium
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg selenium daily for 8 weeks
Study: 14687451
Drug: Ibuprofen/pseudoephedrine modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/pseudoephedrine modified-release capsule (600 mg ibuprofen + 90 mg pseudoephedrine)
Study: 14687451
Drug: Standard formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulations of ibuprofen (400 mg) and pseudoephedrine (60 mg)
Study: 14687451
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing of the slow-release formulation
Study: 26546386
Drug: Nintendo Wii
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nintendo Wii IGC, 5 days of twice daily, 20‐30 min of exercise
Study: 26546386
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation exercise therapy
Study: 24434382
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg twice a day)
Study: 22067763
Drug: Low-dose 91-day
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 91-day extended regimen of 100 mcg levonorgestrel/20 mcg ethinyl estradiol (LNG/EE; 84 days)+10 mcg EE (7 days)
Study: 10065682
Drug: Low-dose erythromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose erythromycin (500 mg b.i.d.) for 8 weeks
Study: 8828358
Drug: Rhubarb (1.0g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb (1.0g administered orally)
Study: 29327047
Drug: Honey gel
Normalized name: DRESSING,HONEY GEL,TOP
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey gel
Study: 19945274
Drug: High-dose epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epidural (0.25% bupivacaine)
Study: 12388962
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (25 micrograms every 4 hours up to six doses)
Study: 12388962
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline solution infusion with oxytocin
Study: 7751531
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (IB) 84 micrograms (two sprays of a 0.06% solution in buffered saline solution)
Study: 7751531
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (IB) 42 micrograms per nostril
Study: 7751531
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (IB) 168 micrograms per nostril
Study: 7751531
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (IB) 84 micrograms per nostril
Study: 7751531
Drug: Vehicle or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle or no treatment
Study: 6587757
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg thrice daily)
Study: 30278429
Drug: 3.6 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g/d ALA plus 190 mg/d quercetin
Study: 29194917
Drug: Exenatide (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (once-weekly extended-release subcutaneous)
Study: 25201358
Drug: FOLFOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil bolus 400 mg/m(2) on day 1, and fluorouracil infusion 2400 mg/m(2) for 46 h, every 2 weeks)
Study: 25201358
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and leucovorin (fluorouracil 380 mg/m(2) and leucovorin 20 mg/m(2) on days 1-5, every 4 weeks)
Study: 20506674
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg per day from day 3 to day 7 of the cycle
Study: 20506674
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg per day on the same cycle days
Study: 11966868
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d. plus tetracycline 500 mg q.i.d. with lansoprazole 30 mg b.i.d. for 7 days (group LAT)
Study: 11966868
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d. plus tetracycline 500 mg q.i.d. with ranitidine bismuth citrate 400 mg b.i.d. for 7 days (group RBCAT)
Study: 11966868
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d. plus doxycycline 100 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days (group LAD)
Study: 7772357
Drug: Succinylcholine (S)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (S) 1 mg/kg
Study: 7772357
Drug: Rocuronium (R)
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium (R) 600 mcg/kg
Study: 7772357
Drug: Rocuronium (R)
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium (R) 150 mcg/kg (open label)
Study: 341951
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg four times daily)
Study: 341951
Drug: Erythromycin with
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin with sulphametopyrazine (1 g at start of exacerbation followed by erythromycin 500 mg four times daily)
Study: 28792952
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day (after crossover from placebo)
Study: 19523672
Drug: Timothy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timothy extract monotherapy (19 microg Phl p 5 daily)
Study: 3497039
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tenoxicam
Study: 3497039
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tenoxicam
Study: 28274268
Drug: True acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: True acupuncture + metformin placebo
Study: 28274268
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture + metformin
Study: 28274268
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture + metformin placebo
Study: 26158468
Drug: Appetitive solutions
Normalized name: APPETITE SUPPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appetitive solutions (juice)
Study: 26158468
Drug: Aversive solutions
Normalized name: DRESSING,VERSIVA XC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aversive solutions (quinine)
Study: 20031956
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (2.5 mg per patch)
Study: 18400322
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment program following the cognitive orientation to daily occupational performance (CO-OP) approach
Study: 12832240
Drug: Divalproex (500-2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex (500-2500 mg/day)
Study: 6469823
Drug: Induced erythrocythemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced erythrocythemia (334 ml of red blood cells)
Study: 22280502
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment in infants with Sulfadoxine‐Pyrimethamine (IPTi‐SP)
Study: 12030736
Drug: Formoterol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (all doses)
Study: 31805985
Drug: SPO2 system
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPO2 system functionality, safety, efficacy, operating costs, nursing knowledge, skills, and retention for oxygen administration
Study: 29309483
Drug: SB-TEAM program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-TEAM program (supervised administration of preventive asthma medication at school and 3 school-based telemedicine visits)
Study: 26926910
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) plus Treatment as Usual (TAU) - up to 12 one-hour weekly sessions.
Study: 26926910
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) alone.
Study: 24436135
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (memantine + donepezil)
Study: 23202836
Drug: Lead exposure
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead exposure in males (6.8 ± 2.0 µg/dL)
Study: 23202836
Drug: Lead exposure
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead exposure in females (5.9 ± 1.9 µg/dL)
Study: 23202836
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with BPb concentrations of 10 µg/dL or above